Open Actively Recruiting

BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis

About

Brief Summary

The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase III

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

  • Unilateral lower extremity DVT occlusion involving iliac and/or common femoral veins with up to 2 cm extension in the inferior vena cava (IVC) or femoral in combination with iliac veins, including patients with extension of clot into the contralateral common iliac vein
  • Acute thrombotic or thromboembolic occlusion with symptom duration of 14 days or less at presentation
  • Frontline treatment with Indigo Aspiration System in the target venous segment per Investigator decision
  • Patient is ≥18 years of age
  • Informed consent is obtained per Institutional Review Board requirements

Exclusion Criteria:

  • Contraindication to systemic or therapeutic doses of anticoagulants
  • Contraindication to iodinated contrast venography that cannot be adequately premedicated
  • Complete infrarenal IVC occlusion
  • In the index leg: prior DVT
  • Prior stent in target venous segment
  • Treatment of index DVT with thrombolytics within 14 days prior to index procedure
  • Pulmonary embolism (PE) defined as either high (systolic blood pressure < 90 mmHg and/or patient on IV vasoactive medication to support blood pressure), or intermediate high-risk PE, as defined by the European Society Guideline on management of PE. Low risk PE and/or intermediate low risk PE can be enrolled.
  • Known coagulation disorders both acquired (e.g., Heparin Induced Thrombocytopenia, etc.) or genetic (e.g., Factor V Leiden, etc.), thrombophilia, or hypercoagulable state
  • Pregnant patients
  • Life expectancy <1 year due to comorbidities
  • Active cancer: metastatic, progressive, or treated with chemotherapy or radiation therapy in the last 6 months, with the exception of patients with non-melanoma primary skin cancers
  • Current participation in another investigational drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies.
  • Other medical, behavioral, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
  • Pre-existing caval or iliofemoral device (e.g. IVC filter, stent obstruction, etc.)
  • Congenital anatomic anomalies of the IVC or iliac veins

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
21-001906
Category
Radiological Sciences
Contact
Tammy Floore
Location
  • UCLA Santa Monica
For Providers
NCT No.
NCT05003843
For detailed technical eligibility, visit ClinicalTrials.gov.